- Agilent Technologies has completed the acquisition of BIOVECTRA, a Canada-based CDMO specialising in biologics and highly potent active pharmaceutical ingredients.
- The acquisition enhances Agilent’s CDMO services and supports gene editing and targeted therapeutic development.
Agilent Technologies Inc. has finalised its acquisition of BIOVECTRA, a Canadian contract development and manufacturing organisation (CDMO). The transaction marks the completion of all regulatory approvals, with BIOVECTRA now officially part of Agilent’s Diagnostics and Genomics Group.
This acquisition allows Agilent to expand its portfolio of CDMO services, particularly in the biologics and gene-editing spaces. The integration of BIOVECTRA brings advanced capabilities to support the development of targeted therapeutics, aligning with the growing demand for these specialised services.
Agilent President and CEO, Padraig McDonnell, commented: “We are delighted to officially welcome the BIOVECTRA team to Agilent. This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutics programs, including best-in-class cGMP pharmaceutical manufacturing.”
Both Agilent and BIOVECTRA operate fully integrated CDMO facilities, adhering to current Good Manufacturing Practices (cGMP), which ensures a high standard of quality in the manufacturing, processing, and packaging of active pharmaceutical ingredients.
